Physician profile
Tam Le
NPI 1336381607
$1,976.47
in general payments reported to CMS, 2019-2025
8 companies · $172 in 2025
The $172 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.87 · 2020: $336 · 2021: $698 · 2022: $261 · 2023: $456 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $628.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $999.91 | 2019-2025 | Repatha, Evenity, Otezla |
| Novo Nordisk INC | $404.75 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.77 | 2021-2023 | Jardiance |
| Abbvie INC. | $140.09 | 2021-2025 | |
| Gilead Sciences, INC. | $95.81 | 2021 | |
| Lilly USA, LLC | $24.98 | 2020 | |
| Janssen Pharmaceuticals, INC | $23.80 | 2021 | |
| Abiomed | $17.36 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tam Le listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.